A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-09-02
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-23 (study day 16); relationship: Y
moderate
assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 56); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-10 (study day 94); relationship: Y
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 150); relationship: not assessed
Data queries
No data queries.